Novo Nordisk A/S (NYSE:NVO) Stock Acquired Rep. Lisa C. McClain

Representative Lisa C. McClain (R-Michigan) recently bought shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on August 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Novo Nordisk A/S stock on June 9th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Autoliv (NYSE:ALV) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of Applied Materials (NASDAQ:AMAT) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of Arthur J. Gallagher & Co. (NYSE:AJG) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of SAP (NYSE:SAP) on 7/22/2025.
• Purchased $1,001 – $15,000 in shares of XPO (NYSE:XPO) on 7/22/2025.
• Purchased $1,001 – $15,000 in shares of Lithia Motors (NYSE:LAD) on 7/22/2025.
• Sold $1,001 – $15,000 in shares of Sanofi (NASDAQ:SNY) on 7/22/2025.
• Sold $1,001 – $15,000 in shares of Waters (NYSE:WAT) on 7/22/2025.
• Purchased $1,001 – $15,000 in shares of Group 1 Automotive (NYSE:GPI) on 7/22/2025.

Novo Nordisk A/S Trading Up 2.6%

NYSE:NVO opened at $56.8910 on Monday. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $254.02 billion, a PE ratio of 15.63, a price-to-earnings-growth ratio of 1.98 and a beta of 0.63. The firm’s 50 day moving average is $62.57 and its 200 day moving average is $69.21. Novo Nordisk A/S has a 12 month low of $45.05 and a 12 month high of $139.74.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.93 by $0.04. The company had revenue of $11.69 billion for the quarter, compared to analysts’ expectations of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, August 26th. Investors of record on Monday, August 18th will be issued a $0.4119 dividend. This represents a dividend yield of 240.0%. The ex-dividend date of this dividend is Monday, August 18th. Novo Nordisk A/S’s payout ratio is 22.53%.

Analyst Upgrades and Downgrades

A number of research firms recently commented on NVO. BNP Paribas raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, August 13th. UBS Group cut shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a report on Tuesday, August 5th. Zacks Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Wednesday, August 20th. Barclays reiterated an “equal weight” rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. Finally, HSBC lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $57.00 price objective for the company. in a research note on Thursday, July 31st. Three analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and a consensus price target of $81.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Saratoga Research & Investment Management grew its position in shares of Novo Nordisk A/S by 4.0% during the 2nd quarter. Saratoga Research & Investment Management now owns 1,512,677 shares of the company’s stock valued at $104,405,000 after purchasing an additional 58,517 shares in the last quarter. Coppell Advisory Solutions LLC purchased a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at $1,963,000. B. Riley Wealth Advisors Inc. purchased a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at $652,000. Marex Group plc purchased a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at $12,497,000. Finally, Advisory Services Network LLC grew its position in shares of Novo Nordisk A/S by 65.0% during the 2nd quarter. Advisory Services Network LLC now owns 88,208 shares of the company’s stock valued at $6,088,000 after purchasing an additional 34,747 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.